logo
  • Home
  • Applications
    • Indications
  • Business
  • EpiSwitch™
  • Products
    • EpiSwitch™ Service
  • Investors
    • Investors Overview
    • Results and Presentations
    • Share Price Information
    • Regulatory News
    • Board & Governance
    • Key Corporate Documents
    • AIM Rule 26
    • Email Alerts
    • Investor Contacts
  • News
  • About Us
    • History
    • Board of Directors
    • Management Team
    • Scientific Advisory Panel
    • Values
    • Careers

Milestones

EpiSwitch™ used in diagnosis of canine lymphoma

Press Release


by Aroul Ramadass

Oxford Biodynamics Plc enters into master service agreement with world leading US pharmaceutical company to evaluate EpiSwitch™ biomarkers

Press Release


by oxfordbiodynamics

OBD joins ALS Biomarker study sponsored by Mitsubishi Tanabe Pharma America

Press Release


by oxfordbiodynamics

Oxford BioDynamics receives Queen's Award for Enterprise

Press Release


by oxfordbiodynamics

Oxford BioDynamics joins Imperial College London in a trial evaluating novel methods of screening for prostate cancer

Press Release


by oxfordbiodynamics

Collaboration agreement with Casa Sollievo della Sofferenza signed for the blood-based diagnosis of Autism Spectrum Disorder

Press Release


by Aroul Ramadass

Fifth collaboration agreement signed in immuno-oncology space

Press Release


by Aroul Ramadass

Consortium including Oxford BioDynamics receives €4 million Horizon 2020 award

Press Release


by Aroul Ramadass

Leading Chinese Healthcare Investment Group Takes Stake in Oxford Biodynamics Plc

Press Release


by oxfordbiodynamics

Canadian patent for EpiSwitch™ granted

Press Release


by Aroul Ramadass

  • 1
  • 2
  • 3
  • …
  • 13

Terms of Use / Site Map / Privacy Policy / Cookies Policy

Regulated and Licensed by Human Tissue Authority
License No. 12571
© 2002-2020 Oxford Biodynamics Plc

Privacy Preference Center

Privacy Preferences

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with this.OkRead more